Trusted Resource for Clinical Trials, Protocols & Progress
Traditional randomized controlled trials (RCTs) are often impractical in rare disease drug development due to small patient populations, genetic heterogeneity, and ethical constraints. In such contexts, real-world evidence (RWE)—clinical data collected outside conventional trials—has emerged as a powerful supplement or even alternative to support regulatory decision-making.
Click to read the full article.
Ongoing clinical trials, especially in the rare disease space, are subject to evolving scientific knowledge, safety data, and logistical hurdles that often necessitate regulatory amendments. Unlike typical trials, rare disease studies frequently encounter unforeseen protocol adjustments due to small patient populations, global enrollment, and early clinical observations. Managing these regulatory changes in real-time is essential to maintain Good Clinical Practice (GCP) compliance and ensure trial integrity.
Click to read the full article.
